Alba Announces Completion of Enrollment and Dosing of Patients in Phase II Clinical Trial of AT-1001 for the Treatment of Celiac Disease

Alba Therapeutics Corporation today announced it has completed enrollment and dosing of patients in its Phase IIa dose ranging clinical trial of AT-1001, the Company's lead orally administered zonulin receptor antagonist drug candidate for the treatment of Celiac Disease (“CD”). The randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the safety, tolerability and efficacy of AT-1001 in 86 CD subjects during gluten challenge.


BALTIMORE, MD, USA | Mar 08, 2007 | 
Alba Therapeutics Corporation today announced it has completed enrollment and dosing of patients in its Phase IIa dose ranging clinical trial of AT-1001, the Company's lead orally administered zonulin receptor antagonist drug candidate for the treatment of Celiac Disease (“CD”). The randomized, double-blind, placebo-controlled clinical trial is designed to evaluate the safety, tolerability and efficacy of AT-1001 in 86 CD subjects during gluten challenge.
"We are pleased with the rapid enrollment of this study and look forward to reporting its results later this year," said Dr. Blake Paterson, CEO of Alba. "Previously reported AT-1001 clinical trial data has been promising and we expect that the results of our ongoing clinical evaluation will support our Phase IIb trial design." The 86 patients enrolled in the Phase IIa study were confirmed biopsy positive for CD and in compliance with a gluten-free diet for at least six months prior to enrollment. Patients were randomized into seven drug-treated and placebo groups and challenged three times a day with gluten for a 14 day period.

About Celiac Disease
Celiac Disease is a T-cell mediated auto-immune disease that occurs in genetically susceptible individuals and is characterized by small intestinal inflammation, injury and intolerance to gluten. According to the National Institutes of Health, CD affects approximately 3 million Americans. The only current treatment for CD is complete elimination of gluten from the diet, which results in remission for some patients.

About AT-1001
AT-1001 is an orally administered octapeptide zonulin receptor antagonist that appears to exert its inhibitory effect on gliadin-induced tight junction disassembly by blocking putative zonulin receptors on the luminal surface of the small intestine. Pretreatment with the peptide fails to inhibit gliadin induced zonulin release, while administration of zonulin analogues or gliadin in the presence of AT-1001 fail to significantly affect intestinal permeability, confirming the effect of the molecule is specific to the zonulin receptor. AT-1001 is currently under investigation in a multicenter, double blind, placebo controlled Phase II dose ranging study to evaluate the safety, tolerability and efficacy of AT-1001 in 86 CD subjects during gluten challenge.

About Alba
Alba Therapeutics Corporation is a privately held biopharmaceutical company based in Baltimore, Maryland. Alba is dedicated to commercializing disease-modifying therapeutics and vaccine and drug delivery adjuvants based on the zonulin pathway. Alba’s lead compound, AT-1001, is targeted towards the treatment of Celiac Disease, Inflammatory Bowel Disease and Type 1 Diabetes.

Contact: Stuart Sedlack, SVP, Corporate Development
Phone: 410-319-0780
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Web site: http://www.albatherapeutics.com

back to top
line

March 05, 2007
Alba Therapeutics Appoints Dr. Linda Arterburn to Head Pharmacology and Toxicology Department

BALTIMORE, Maryland - Alba Pharmaceuticals Corporation today announced the appointment of Linda M. Arterburn, Ph.D. as its Senior Director, In Vivo Pharmacology & Toxicology. Dr. Arterburn will be responsible for leading Alba’s in vivo pharmacology and toxicology efforts supporting the Company’s zonulin antagonist and agonist programs.

“We are very pleased that Dr. Arterburn is joining Alba” said Blake Paterson, M.D., Chief Executive Officer of Alba Therapeutics. “Linda is an accomplished scientific executive and brings a broad range of biotechnology research and development management experience to Alba.”

Prior to joining Alba, Dr. Arterburn was Executive Director of Discovery Research at Martek Biosciences. In this capacity, she initiated and led an inflammation research program and was lead inventor of several patents involving novel anti-inflammatory molecules. She previously led Clinical Research and Scientific Affairs at Martek where she played a key role in the regulatory authorizations for the addition of Martek’s fatty acid products, DHA and ARA, to infant formula in the United States and Canada. Dr. Arterburn also spent seven years at W.R. Grace & Co., where she led in vitro toxicology research programs, and then served as Manager of Technology and Planning for the research portfolio of this Fortune 100 company.

Dr. Arterburn holds a PhD in Pharmacology and the Molecular Sciences from the Johns Hopkins University School of Medicine, and a Bachelor’s Degree in Biochemistry from the University of Wisconsin.

About Alba
Alba Therapeutics Corporation is a privately held biopharmaceutical company based in Baltimore, Maryland. Alba is dedicated to commercializing disease-modifying therapeutics and vaccine and drug delivery adjuvants based on the zonulin pathway. Alba’s lead molecule, AT-1001, is targeted towards the treatment of Celiac Disease and other autoimmune diseases including IBD and Type 1 Diabetes. AT-1001 is currently under investigation in a multicenter, double blind, placebo controlled Phase II dose ranging study to evaluate the safety, tolerability and efficacy of AT-1001 in 86 Celiac Disease subjects during gluten challenge.

Contact: Stuart Sedlack, SVP, Corporate Development
Phone: 410-319-0780
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Web site: http://www.albatherapeutics.com

back to top
line

January 09, 2007
Alba Therapeutics Appoints Dr. Sefik S. Alkan to Lead Discovery Efforts

Baltimore - Alba Therapeutics Corporation today announced the appointment of Sefik S. Alkan, Ph.D. as its Executive Vice President, Discovery. Dr. Alkan will be responsible for leading Alba’s biology, chemistry and analytical product development activities.

“We are delighted to announce the appointment of Sefik as our Executive Vice President, Discovery,” said Blake Paterson, M.D., Chief Executive Officer of Alba Therapeutics. “Sefik’s appointment confirms our commitment to leading research efforts in mucosal biology, barrier function, and innate immunity. Sefik is an accomplished scientific executive with over twenty-five years of leadership in drug discovery and management with top pharmaceutical companies including Hoechst Marion Roussel, Aventis, Novartis and 3M Pharmaceuticals. His experience, which ranges from inflammation, autoimmune diseases, allergy and asthma to oncology and immunology, is a great compliment to our product development strategy,” Dr. Paterson added.

Prior to joining Alba, Dr. Alkan headed the Immunology Department at 3M Corporation’s Pharmaceutical Division, leading research efforts in Toll-Like Receptor (TLR) agonists as vaccine adjuvants and in tumor therapy. From 1998 to 2003, Dr. Alkan headed Hoechst Marion Roussel’s (now Sanofi-Aventis) Biochemistry and Immunology department. From 1980 to 1998, Dr. Alkan worked for Novartis Pharma AG (formerly Ciba-Geigy) in Basel, Switzerland leading drug discovery efforts focused on type I/II interferons, monoclonal antibodies and transcriptional regulation of Th1/Th2 cytokines in roles of increasing responsibility. Before joining the pharmaceutical industry, Dr. Alkan spent 3 years at the renowned Basel Institute of Immunology, Switzerland, studying the molecular mechanisms of the interactions between APC, T-helper cells and B cells.

Dr. Alkan was a postdoctoral fellow in the Department of Microbiology at the University of California, San Francisco and holds a Ph.D. in Immunology and Microbiology and a B.S. degree in Health Sciences from the University of Hacettepe, Ankara, Turkey. Sefik Alkan has published 74 original research articles, 16 review articles and book chapters, and has been awarded 23 patents.

About Alba
Alba Therapeutics Corporation is a privately held biopharmaceutical company based in Baltimore, Maryland. Alba is dedicated to commercializing disease-modifying therapeutics and vaccine and drug delivery adjuvants based on the zonulin pathway. Alba’s lead molecule, AT-1001, is targeted towards the treatment of Celiac Disease and other autoimmune diseases including IBD and Type 1 Diabetes. AT-1001 is currently under investigation in a multicenter, double blind, placebo controlled Phase II dose ranging study to evaluate the safety, tolerability and efficacy of AT-1001 in 79 Celiac Disease subjects during gluten challenge.

Contact: Stuart Sedlack, SVP, Corporate Development
Phone: 410-319-0780
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Web site: http://www.albatherapeutics.com

SOUREC: Alba Therapeutics Corp

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top